Suganthi Balasubramanian - 03 Apr 2023 Form 3 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
3
Accepted by SEC
14 Apr 2023, 11:30:38 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Suganthi Balasubramanian

Key filing fact

Suganthi Balasubramanian filed Form 3 for BioXcel Therapeutics, Inc. (BTAI) on 14 Apr 2023.

Key facts

  • This page summarizes Suganthi Balasubramanian's Form 3 filing for BioXcel Therapeutics, Inc. (BTAI).
  • 0 reported transactions and 0 derivative rows are listed below.
  • Accepted by SEC: 14 Apr 2023, 11:30.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BTAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
8,546,750
Date
03 Apr 2023
Ownership
By BioXcel LLC
BTAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,000
Date
03 Apr 2023
Ownership
See Footnote
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person may be deemed to share investment control over shares of common stock of the Issuer held by BioXcel and 1,000 additional shares of common stock held in a trust. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein, if any. This filing shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares of common stock for the purpose of Section 16 or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .